Clinical trials: Lymphatic Filariases
Malaria, Lymphatic Filariasis
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
The purpose of this study is to determine whether repeated ivermectin mass drug administrations to Burkinabé villagers, performed in three week intervals over the rainy-season, is well-tolerated and safe, and also effective in…
- Trial name
- RIMDAMAL (NCT02509481)
- Testing
- Ivermectin, Albendazole
- Where
- 2 sites in United States, Burkina Faso
- Volunteers
- 2,712 people, healthy volunteers welcome
- Sponsor
- Colorado State University
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Lymphatic Filariasis
Moxidectin for LF, Cote d'Ivoire (DOLF)
The purpose of this study is to determine whether moxidectin (Mox) will be more effective than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis (LF).
- Trial name
- NCT04410406
- Testing
- Ivermectin, Diethylcarbamazine, Albendazole
- Where
- Côte d’Ivoire
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Non-filarial Elephantiasis
An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis
An RCT (n=193) in two podoconiosis clinics in Ethiopia to evaluate the effectiveness of a research based skin management regimen compared to the current regimen.
- Trial name
- NCT02839772
- Testing
- Current skin care regimen plus 2% glycerine added to soaking water, Current skin care regimen
- Volunteers
- 193 people
- Sponsor
- University of Hull
Lymphatic Filariasis
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
This study is conducted in Kerala, India. It will determine whether a new treatment regimen of albendazole and diethylcarbamazine (DEC) for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
- Trial name
- NCT00511004
- Testing
- Albendazole, Diethylcarbamazine
- Where
- India
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphatic Filariasis
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
Albendazole and ivermectin are currently used in combination for annual mass treatment of lymphatic filariasis in Africa. Although the drugs have been donated, the cost of such programmes is very high and has proven to be a major…
- Trial name
- FED (NCT01213576)
- Testing
- Albendazole 400mg and ivermectin 200mcg/kg, Albendazole and ivermectin, albendazole 800mg and ivermectin 400mcg/kg bi-annually
- Where
- Malawi
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Lymphatic Filariasis
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
According to the World Health Organization, lymphatic filariasis, a mosquito-borne parasitic disease, is the second leading cause of disability worldwide.
- Trial name
- NCT01629771
- Where
- 2 sites in United States, India
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Northwestern University